The cost-effectiveness of elective Cesarean delivery for HIV-infected women with detectable HIV RNA during pregnancy
- PMID: 11101066
- DOI: 10.1097/00002030-200011100-00017
The cost-effectiveness of elective Cesarean delivery for HIV-infected women with detectable HIV RNA during pregnancy
Abstract
Objectives: To determine the net health consequences, costs, and cost-effectiveness of alternative delivery strategies for HIV-infected pregnant women with detectable HIV RNA in the USA.
Design: Cost-effectiveness analysis using a probabilistic decision model.
Methods: The model compared two strategies: elective Cesarean section and vaginal delivery. Data for HIV transmission rate, maternal death rate, health-related quality of life and costs were obtained from the literature, national databases, and a tertiary hospital's cost accounting system. Model outcomes included total lifetime costs, quality-adjusted life expectancy, maternal death rate, HIV transmission rate, and incremental cost-effectiveness ratios.
Results: Elective Cesarean section resulted in a vertical HIV transmission rate of 34.9 per 1000 births compared with 62.3 per 1000 births for vaginal delivery. Elective Cesarean section was more effective (38.7 quality adjusted life years per mother and child pair) and less costly ($10600 per delivery) than trial of labor (38.2 combined quality adjusted life years at a cost of $14500 per delivery). However, elective Cesarean section increased maternal mortality by 2.4 deaths per 100000 deliveries. The results were consistent over a wide range of the variables, but were sensitive to the risk of HIV transmission with vaginal delivery and the relative risk of HIV transmission with elective Cesarean section.
Conclusions: In pregnant HIV-infected women with detectable HIV RNA, elective Cesarean section would reduce total costs and increase overall quality-adjusted life expectancy for the mother-child pair, albeit at a slight loss of quality adjusted life expectancy to the mother.
Comment in
-
Fighting global AIDS: the value of cost-effectiveness analysis.AIDS. 2000 Nov 10;14(16):2609-10. doi: 10.1097/00002030-200011100-00026. AIDS. 2000. PMID: 11101075 No abstract available.
Similar articles
-
The cost-effectiveness of elective Cesarean delivery to prevent hepatitis C transmission in HIV-coinfected women.AIDS. 2004 Sep 3;18(13):1827-34. doi: 10.1097/00002030-200409030-00012. AIDS. 2004. PMID: 15316344
-
Cost-effectiveness of cesarean section delivery to prevent mother-to-child transmission of HIV-1.AIDS. 2000 Apr 14;14(6):691-700. doi: 10.1097/00002030-200004140-00008. AIDS. 2000. PMID: 10807192
-
Point-of-care HIV viral load in pregnant women without prenatal care: a cost-effectiveness analysis.Am J Obstet Gynecol. 2019 Sep;221(3):265.e1-265.e9. doi: 10.1016/j.ajog.2019.06.021. Epub 2019 Jun 20. Am J Obstet Gynecol. 2019. PMID: 31229430
-
Cesarean delivery for HIV-infected women: recommendations and controversies.Am J Obstet Gynecol. 2007 Sep;197(3 Suppl):S96-100. doi: 10.1016/j.ajog.2007.02.034. Am J Obstet Gynecol. 2007. PMID: 17825656 Review.
-
Cesarean section delivery to prevent vertical transmission of human immunodeficiency virus type 1. Associated risks and other considerations.Ann N Y Acad Sci. 2000 Nov;918:115-21. doi: 10.1111/j.1749-6632.2000.tb05479.x. Ann N Y Acad Sci. 2000. PMID: 11131694 Review.
Cited by
-
The cost-effectiveness of directly observed highly-active antiretroviral therapy in the third trimester in HIV-infected pregnant women.PLoS One. 2010 Apr 13;5(4):e10154. doi: 10.1371/journal.pone.0010154. PLoS One. 2010. PMID: 20405011 Free PMC article.
-
Chronic illness burden and quality of life in an aging HIV population.AIDS Care. 2013;25(4):451-8. doi: 10.1080/09540121.2012.712669. Epub 2012 Aug 15. AIDS Care. 2013. PMID: 22894702 Free PMC article.
-
A Systematic Review of Methods and Practice for Integrating Maternal, Fetal, and Child Health Outcomes, and Family Spillover Effects into Cost-Utility Analyses.Pharmacoeconomics. 2024 Aug;42(8):843-863. doi: 10.1007/s40273-024-01397-5. Epub 2024 May 31. Pharmacoeconomics. 2024. PMID: 38819718 Free PMC article.
-
The Cost-Effectiveness of HIV/STI Prevention in High-Income Countries with Concentrated Epidemic Settings: A Scoping Review.AIDS Behav. 2022 Jul;26(7):2279-2298. doi: 10.1007/s10461-022-03583-y. Epub 2022 Jan 15. AIDS Behav. 2022. PMID: 35034238 Free PMC article.
-
Universal Rapid Human Immunodeficiency Virus Screening at Delivery: A Cost-Effectiveness Analysis.Infect Dis Obstet Gynecol. 2018 Mar 14;2018:6024698. doi: 10.1155/2018/6024698. eCollection 2018. Infect Dis Obstet Gynecol. 2018. PMID: 29731602 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical